Uwe Reuter, EAN 2020 – Characteristics of the HER-MES trial in episodic and chronic migraine
Uwe Reuter (Charité Universitätsmedizin Berlin, Germany) talks to us about the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine (ClinicalTrials.gov Identifier: NCT03828539).
1. What are the unmet needs in the treatment of episodic migraine? (0:05)
2. Could you tell us a little about the objectives and design of the HER-MES study of erenumab vs topiramate? (1:13)
3. What have been the findings of the study so far? (3:10)
4. What has been the impact of antibodies targeting calcitonin gene-related peptide (CGRP) on the treatment landscape for episodic migraine? (4:44)
5. How do you see the treatment of episodic migraine progressing in the next 5 years? (6:50)
Speaker disclosure: Uwe Reuter reports having received honoraria for consulting and lectures within the past 3 years from Amgen, PharmAllergan, Eli Lilly, Lundbeck, Novartis Pharma, Hormosan Pharma, electroCore, Medscape, Novartis, StreaMedUp and Teva, he holds no stocks of pharmaceutical companies or medical device companies.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Share this Video
Related Videos In Headache Disorders
Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]
Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023
Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]
Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!